Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers

被引:293
|
作者
Scheuer, L
Kauff, N
Robson, M
Kelly, B
Barakat, R
Satagopan, J
Ellis, N
Hensley, M
Boyd, J
Borgen, P
Norton, L
Offit, K
机构
[1] Mem Sloan Kettering Canc Ctr, Clin Genet Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dev Chemotherapy Serv, Dept Med, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast & Gynecol Serv, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
关键词
D O I
10.1200/JCO.2002.20.5.1260
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : To prospectively determine the impact of genetic counseling and testing on risk-reduction strategies and cancer incidence in a cohort of individuals at hereditary risk for breast and ovarian cancer. Patients and Methods: Two hundred fifty-one individuals with BRCA mutations were identified at a single comprehensive cancer center from May 1, 1995, through October 31, 2000. Uniform recommendations regarding screening and preventive surgery were provided in the context of genetic counseling. Patients were followed for a mean of 24.8 months (range, 1.6 to 66.0 months) using standardised questionnaires, chart reviews, and contact with primary physicians. Results: Frequency of cancer surveillance by physical examinations and imaging studies increased after genetic counseling and testing. Twenty-one breast, ovarian, primary peritoneal, or fallopian tube cancers were detected after receipt of genetic test results. Among 29 individuals choosing risk-reducing mastectomy after testing, two were found to have occult intraductal breast cancers. Among 90 individuals who underwent risk-reducing salpingo-oophorectomy, one early-stage ovarian neoplasm and one early-stage fallopion tube neoplasm were found. Radiographic or tumor marker-based screening detected six breast cancers, five of which were stage 0/I, one early-stage primary peritoneal cancer, and three stage I or II ovarian cancers. Six additional breast cancers were detected by physical examination between radiographic screening intervals; four of these six tumors were stage I. No stage III or stage IV malignancies were detected after genetic testing. Conclusion: This study provides prospective evidence that genetic counseling and testing increased surveillance and led to risk-reducing operations, which resulted in diagnosis of early-stage tumors in patients with BRCA1 and BRCA2 mutations. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:1260 / 1268
页数:9
相关论文
共 50 条
  • [21] Prophylactic surgery in women with inherited risk of breast and ovarian cancer (BRCA1/2 mutation carriers)
    Giard, S.
    E-MEMOIRES DE L ACADEMIE NATIONALE DE CHIRURGIE, 2011, 10 (02): : 60 - 63
  • [22] Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer
    Nanez, Andrea
    Stram, Douglas A.
    Powell, C. Bethan
    Garcia, Christine
    GYNECOLOGIC ONCOLOGY REPORTS, 2022, 39
  • [23] Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation
    Wainberg, S
    Husted, J
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (12) : 1989 - 1995
  • [24] Obesity is associated with poor clinical outcome in BRCA mutation carriers with epithelial ovarian cancer
    John, Catherine
    Cass, Ilana
    Walsh, Christine
    RimelBj, Bobbie J.
    Taylor, Kristin N.
    Li, Andrew John
    GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : E27 - E27
  • [25] Ovarian Cancer in BRCA Mutation Carriers: Improved Outcome After Intraperitoneal (IP) Cisplatin
    Maryann Kwa
    Susan Edwards
    Andrea Downey
    Elsa Reich
    Robert Wallach
    John Curtin
    Franco Muggia
    Annals of Surgical Oncology, 2014, 21 : 1468 - 1473
  • [26] Ovarian Cancer in BRCA Mutation Carriers: Improved Outcome After Intraperitoneal (IP) Cisplatin
    Kwa, Maryann
    Edwards, Susan
    Downey, Andrea
    Reich, Elsa
    Wallach, Robert
    Curtin, John
    Muggia, Franco
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (05) : 1468 - 1473
  • [27] Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers
    Milne, Roger L.
    Antoniou, Antonis C.
    ENDOCRINE-RELATED CANCER, 2016, 23 (10) : T69 - T84
  • [28] Ovarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers
    DiSilvestro, Jessica
    Dexter, Julia
    Haddad, Jessica
    Beffa, Lindsey
    Raker, Christina
    Laprise, Jessica
    Wilbur, Jennifer Scalia
    Clark, Melissa
    Bradford, Leslie
    Brown, Amy
    Hofstatter, Erin
    Dalela, Disha
    Toland, Maris
    Robison, Katina
    Stuckey, Ashley
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S195 - S196
  • [29] Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
    van der Velde, Nienke M.
    Mourits, Marian J. E.
    Arts, Henriette J. G.
    de Vries, Jacob
    Leegte, Beike K.
    Dijkhuis, Grieteke
    Osterwijk, Jan C.
    de Bock, Geertruida H.
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (04) : 919 - 923
  • [30] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Milne, Roger L.
    Osorio, Ana
    Ramon y Cajal, Teresa
    Baiget, Montserrat
    Lasa, Adriana
    Diaz-Rubio, Eduardo
    de la Hoya, Miguel
    Caldes, Trinidad
    Teule, Alex
    Lazaro, Conxi
    Blanco, Ignacio
    Balmana, Judith
    Sanchez-Olle, Gessami
    Vega, Ana
    Blanco, Ana
    Chirivella, Isabel
    Esteban Cardenosa, Eva
    Duran, Mercedes
    Velasco, Eladio
    Martinez de Duenas, Eduardo
    Tejada, Maria-Isabel
    Miramar, Maria-Dolores
    Calvo, Maria-Teresa
    Guillen-Ponce, Carmen
    Salazar, Raquel
    San Roman, Carlos
    Urioste, Miguel
    Benitez, Javier
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 221 - 232